Sublingual immunotherapy - questions of efficiency and safety



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The basic results of clinical researches on efficacy and safety studying sublingual allergenspecific immunotherapy (slASIT) are presented in the review. The results of SUBLINGUAL application of allergens in Russian Federation are presented.

Full Text

Restricted Access

About the authors

M V Manzhos

NOU VPO the medical institute «Reaviz»

Email: mmv_kinel@mail.ru
Samara, Russia

E S Fedenko

Institute of Immunology

Moscow, Russia

M A Myagkova

Institute physiologically active substances of the Russian Academy of Science

Moscow, Russia

References

  1. Гущин И.С. Физиология иммунитета и аллергия. Физиология и патология иммунной системы. 2004, № 9, с. 17-20.
  2. Black J.H. The oral administration of pollen. J. Lab. Clin. Med. 1927, v. 12, p. 1156.
  3. Morris D. Use of sublingual antigen in diagnosis and treatment of food allergy. Ann. Allergy. 1969, v. 27 (6), p. 289-294.
  4. Penagos M., Passalacqua G., Compalati E. et al. Meta-analysis of the efficacy of sublingual immunotherapy in allergic asthma in pediatric patient 3 to 18 years of age. Chest. 2008, v. 133, p. 599-609.
  5. Scadding K., Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin. Allergy, 1986, v. 16, p. 483-491.
  6. Tari M.G., Mancino M., Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double blind study. Allergol. Immunopathol. 1990, v. 18 (5), p. 277-284.
  7. Passalacqua, Giovanni et al. Randomized controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced. The Lancet. 1998, v. 351, p. 629-632.
  8. Malling H., Weeke B. et al. Immunotherapy. Position Paper of the European Academy of Allergy and Clinical Immunology Allergy. 1993, v. 48 (14), p. 9-35.
  9. Bousquet J., Lockey R., Malling H.J. et al. World Health Organization Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1998, v. 53, p. 1-42.
  10. Malling H.J., Abreu-Nogueira J., Alvarez-Cuesta E. et al. EAACI Position Paper on local immunotherapy. Allergy. 1998, v. 53, p. 933-944.
  11. Bousquet J., Van Cauwenberge P. et al. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. 2001, v. 108, suppl. 5, p. 147-334.
  12. Bousquet J., Khaltaev N., Cruz A.A. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) Ed. Allergy. 2008, v. 63, suppl. 86, p. 8-160.
  13. Canonica G.W., Bousquet J., Casale T. et al. Sub-Lingual Immunotherapy: World Allergy Organization Position Paper 2009. World Allergy Organization Journal: November 2009, v. 2, p. 233-281.
  14. Coifman R.E., Cox L.S. 2006 American Academy of Allergy, Asthma & Immunology member immunotherapy practice patterns and concerns. J. Allergy Clin. Immunol. 2007, v. 119, p. 1012-1013.
  15. Cox L. Sublingual immunotherapy and allergic rhinitis. Curr. Allergy Asthma. 2008, Rep. 8 (2), p. 102-110.
  16. Madonini E., Agostinis F., Barra R. et al. Long-term and preventive effects of sublingual allergen-specific immunotherapy: a retrospective, multicentre study. Int. J. Immunopathol Pharmacol. 2003, v. 16 (l), p. 73-79.
  17. Novembre E., Galli E. et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 2004, v. 114 (4), p. 851-857.
  18. Moingeon P., Batard T, Fadel R. et al. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy. 2006, v. 61, p. 151-165.
  19. Pajno G., Vita D., Parmiani S. et al. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin. Exp. Allergy. 2003, v. 33, p. 1641-1647.
  20. Stelmach I., Kaczmarek-Wozniak J., Majak P. et al. Efficacy and safety of high-doses sublingual immunotherapy in ultrarush scheme in children allergic to grass pollen. Clin. Exp. Allergy. 2009, v. 39, p. 401-408.
  21. Mortemousque B., Bertel F., De Casamayor J. et al. House dust mite sublingualswallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study. Clin. Exp. Allergy. 2003, v. 33, p. 464-469.
  22. Passalacqua G., Pawankar R., Baena-Cagnani C., Canonica G. Sublingual immunotherapy: where do we stand? Present and future. Curr. Opin. Allergy Clin. Immunol. 2009, v. 9, p. 1-3.
  23. Canonica G.W, Baena Cagnani C., Bousquet J. et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007, v. 62, p. 317-324.
  24. Wilson A.M., O’Byrne P.M., Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am. J. Med. 2004, v. 116, p. 338-344.
  25. Marcucci F., Sensi L., Di Cara G. et al. Dose dependence of immunological response to sublingual immunotherapy Allergy 2005, v. 60, p. 952-956.
  26. Calderon M.A., Rak S., Durham S.R. Grass Pollen Tablets for Sublingual Immunotherapy in seasonal allergic rhinitis. AAAAI. 2005, v. 115, p. 65.
  27. Calamita Z., Saconato H., Pela A.B., Atallah A.N. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized clinical trials using the Cochrane collaboration method. Allergy. 2006, v. 61, p. 1162-1172.
  28. Olaguibel J.M., Alvarez Puebla M.J. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J. Investig. Allergol Clin. Immunol. 2005, v. 15 (1), p. 9-16.
  29. Wilson D.R., Lima M.I., Durham S.R. Sublingual immunotherapy for allergic rhinitis: systematic review and metaanalysis. Allergy. 2005, v. 60 (l), p. 4-12.
  30. Penagos M., Compalati E., Tarantini F. et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann. Allergy Asthma Immunol. 2006, v. 97 (2), p. 141-148.
  31. Malling H.J. Is sublingual immunotherapy clinically effective? Curr. Opin. Allergy Clin. Immunol. 2002, v. 2 (6), p. 523-531.
  32. Nieto A., Mazon A., Pamies R. et al. Sublingual immunotherapy for allergic respiratory diseases: An evaluation of meta-analyses. J. Allergy Clin. Immunol. 2009, v. 124 (1), p. 157-161.
  33. Quirino T, Iemoli E., Siciliani E. et al. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double-blind double-dummy study. Clin. Exp. Allergy. 1996, v. 26, p. 1253-1261.
  34. Mungan D., Misirligil Z., Gurbuz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite sensitive patients with rhinitis and asthma: a placebocontrolled study. Ann. Allergy Asthma Immunol. 1999, v. 82, p. 485-490.
  35. Khinchi M.S., Poulsen L.K., Carat F. et al. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, doubleblind, double-dummy study. Allergy. 2004, v 59 (1), p. 45-53.
  36. Passalacqua G., Canonica G.W Sublingual or injection immunotherapy: the final answer? Allergy. 2004, v. 59 (3), p. 37-38.
  37. Della Volpe A., DAgostino G.W., Varricchio A.M. et al. Sublingual allergen-specific immunotherapy in allergic rhinitis and related pathologies: Efficacy in a paediatric population. Int. J. Immunopathol. Pharmacol. 2002, v. 15 (l), p. 35-40.
  38. Михайлов Е.Л. Пероральная специфическая гипосенсибилизация амброзийного поллиноза. Автореф. диссертации канд. мед. наук. М., 1978, 20 с.
  39. Roder E., Berger M.Y., Hop W.C. et al. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J. Allergy Clin. Immunol. 2007, v. 119, p. 892-898.
  40. Reider N. Sublingual immunotherapy for allergic rhinoconjunctivitis — the seeming and the real. Int. Arch. Allergy Immunol. 2005, v. 137 (3), p. 181-186.
  41. Bufe A., Ziegler-Kirbach E., Stoeckmann E. et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy. 2004, v. 59 (5), p. 498-504.
  42. Ricardo J.S., Lozano A., Caceres M.E. et al. Allergen immunotherapy for prevention and treatment of respiratory allergy in childhood. Arch. argent. pediatr. 2010, v 108 (3), p. 258-265.
  43. Курбачева О.М. Сублингвальная аллерген-специфическая иммунотерапия — метод системного лечения атопических заболеваний. Рос. Аллергол. Журн. 2006, № 6, с. 3-9.
  44. Pajno G.B., Passalacqua G., Vita D. et al. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria — induced respiratory allergy: a randomized controlled trial. Allergy. 2004, v. 59 (8), p. 883-887.
  45. Marogna M., Spadolini I., MIassolo A. et al. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J. Allergy Clin. Immunol. 2005, v. 15 (6), p. 1184-1188.
  46. De Groot H., Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy. 2009, v. 64, p. 963-964.
  47. Stewart G.E., Lockey R.F. Systemic reactions from allergen immunotherapy. J. Allergy Clin. Immunol. 1992, v. 90, p. 567-578.
  48. Amin H.S., Liss G.M., Bernstein D.I. Evaluation ofnear-fatal reactions to allergen immunotherapy injections. J. Allergy Clin. Immunol. 2006, v. 117, p. 169-175.
  49. Andre C., Vatrinet C. et al. Safety of sublingual-swallow immunotherapy in children and adults. Int. Arch. Allergy Immunol. 2000, v. 121 (3), p. 229-234.
  50. Agostinis F., Foglia C., Landi M. et al. The safety of sublingual immunotherapy with one or multiple pollen allergens in children. Allergy. 2008, v. 63, p. 1637-1639.
  51. Lombardi C., Gargioni S., Cottini M. et al. The safety of sublingual immunotherapy with one or more allergens in adults. Allergy. 2008, v. 63, p. 375-376.
  52. Gidaro G.B., Marcucci F., Sensi L. et al. The safety of sublin-gual-swallow immunotherapy: an analysis of published studies. Clin. Exp. Allergy. 2005, v. 35 (5), p. 565-571.
  53. Gammeri E., Arena A., D’Anneo R. et al. Safety and toler-ability of ultra-rush (20minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma. Allergol. Imrnimopathol. 2005, v. 33 (4), p. 221-223.
  54. Балаболкин И.И., Кувшинова Е.Д., Ксензова Л.Д. и соавт. Эффективность сублингвальной аллерген-специфичес-кой иммунотерапии детей, страдающих поллинозами. Аллергология и иммунология. 2001, № 2, с. 171-174.
  55. Передкова Е.В., Медуницин Н.В., Порошина Ю.А. Пероральный метод специфической иммунотерапии поллинозов. Иммунология. 1986, № 6, с. 49-51.
  56. Смолкин Ю.С., Ветров В.П., Страхова М.С. Иммунотерапия при атопических заболеваниях у детей. Рос. медиц. журн. 1998, № 6, с. 50-54.
  57. Радунская С.Ф., Лавренчик Е.И., Михеева Г. Н., Балаболкин И.И. и соавт. Результаты применения в РФ пе-роральных аллергенов фирмы «Sevac» («СЕВАФАРМА», Чехия) для специфической иммунотерапии поллинозов. Сб. научн. трудов «Современные проблемы аллергологии, клинической иммунологии и иммунофармакологии», М., 1998, с. 711.
  58. Ревякина В.А., Арсентьева Н.А., Филатова Т.А. Эффективность аллерген-специфической иммунотерапии пероральными аллергенами «Весенняя смесь ранняя» у детей с поллинозом. Рос. Аллергол. Журн. 2007, № 2, с. 63-67.
  59. Манжос М.В., Феденко Е.С., Мягкова М.А. и соавт. Клиническая эффективность различных схем сублингвальной аллерген-специфической иммунотерапии при поллинозе. Рос. Аллергол. Журн. 2008, № 3, с. 27-31.
  60. Горячкина Л.А., Ненашева Н.М., Дробик О.С., Бжедуго-ва Е.З. Локальная аллерген-специфическая иммунотерапия. Пособие для врачей. М., 2008, 34 с.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2012



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies